Anmelden Kostenlos registrieren

Adma Biologics Inc % des Leerverkaufs (short % of float)

Was ist das % des Leerverkaufs (short % of float) von Adma Biologics Inc?

% des Leerverkaufs (short % of float) von Adma Biologics Inc ist 13.70%

Was ist die Definition von % des Leerverkaufs (short % of float)?



% des Leerverkaufs (Short % of Float) ist die Menge der Aktien, die im Leerverkauf verkauft worden sind, die im Vergleich zum Float in Prozent ausgedrückt wird.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% des Leerverkaufs (short % of float) von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adma Biologics Inc

Was macht Adma Biologics Inc?

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Unternehmen mit % des leerverkaufs (short % of float) ähnlich Adma Biologics Inc